TWi Pharmaceuticals Inc (4180)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:TWi Pharmaceuticals Inc (4180) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013456
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
TWi Pharmaceuticals Inc (TWi), formerly Anchen Pharmaceuticals (Taiwan) Inc is a manufacturer of high barrier generics drugs. The company’s products include donepezil hydrochloride tablets, hydroquinone cream, hydroquinone time release cream, megestrol acetate oral suspension and nifedipine extended-release tablets. Its drugs consists of oral controlled release dosage form, non-oral parental and transdermal products, novel drug delivery systems, and polymeric oral delivery systems. The company develops oral high barrier generic prescription products for muscle relaxants, hypertension, vasospatic agina, anorexia, cachexia, alzheimar’s diseases, and others. TWi is headquartered in Taipei, Taiwan.

TWi Pharmaceuticals Inc (4180) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
TWi Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
TWi Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
TWi Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
TWi Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
TWi Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
TWi Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Castle Creek Pharma Enters into Licensing Agreement with TWi Biotechnology 10
Industrial Technology Research Institute Enters Into Licensing Agreement With TWI Biotech For ITRI-260 11
Equity Offering 12
TWi Biotechnology to Raise USD17.5 Million in IPO 12
TWi Pharma Raises USD87 Million in Public Offering of Global Depository Receipts 13
TWi Pharma Completes IPO 14
TWi Pharma Announces Private Placement Of Shares For US$11 Million 15
Acquisition 16
TWi Pharmaceutical Cayman to Sell its Stake in Hainan-Based Pharmaceuticals Company for USD28.6 Million 16
TWi Pharma to Acquire 50% Stake in Hainan Visum Pharma 17
TWi Pharma Acquires U-Liang Pharma 18
TWi Pharmaceuticals Inc – Key Competitors 19
TWi Pharmaceuticals Inc – Key Employees 20
TWi Pharmaceuticals Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
TWi Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
TWi Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
TWi Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
TWi Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
TWi Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
TWi Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Castle Creek Pharma Enters into Licensing Agreement with TWi Biotechnology 10
Industrial Technology Research Institute Enters Into Licensing Agreement With TWI Biotech For ITRI-260 11
TWi Biotechnology to Raise USD17.5 Million in IPO 12
TWi Pharma Raises USD87 Million in Public Offering of Global Depository Receipts 13
TWi Pharma Completes IPO 14
TWi Pharma Announces Private Placement Of Shares For US$11 Million 15
TWi Pharmaceutical Cayman to Sell its Stake in Hainan-Based Pharmaceuticals Company for USD28.6 Million 16
TWi Pharma to Acquire 50% Stake in Hainan Visum Pharma 17
TWi Pharma Acquires U-Liang Pharma 18
TWi Pharmaceuticals Inc, Key Competitors 19
TWi Pharmaceuticals Inc, Key Employees 20
TWi Pharmaceuticals Inc, Other Locations 21
TWi Pharmaceuticals Inc, Subsidiaries 21

★海外企業調査レポート[TWi Pharmaceuticals Inc (4180)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • DiaCarta Inc-医療機器分野:企業M&A・提携分析
    Summary DiaCarta Inc (DiaCarta) develops and commercializes molecular diagnostics products for cancer and infectious diseases. The company offers genomic testing for biomarkers and also provides clinical sample testing services in their CLIA-certified lab. It offers products such as gene mutation de …
  • Myriad Group AG:企業の戦略的SWOT分析
    Myriad Group AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Labeyrie Fine Foods:企業の戦略・SWOT・財務分析
    Labeyrie Fine Foods - Strategy, SWOT and Corporate Finance Report Summary Labeyrie Fine Foods - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Proengin:企業の戦略・SWOT・財務情報
    Proengin - Strategy, SWOT and Corporate Finance Report Summary Proengin - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Arab African International Bank:企業の戦略・SWOT・財務情報
    Arab African International Bank - Strategy, SWOT and Corporate Finance Report Summary Arab African International Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Siltech Corp:企業の戦略的SWOT分析
    Siltech Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • UCB S.A.:企業の戦略・SWOT・財務分析
    UCB S.A. - Strategy, SWOT and Corporate Finance Report Summary UCB S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • EDF Renewable Energy Inc-エネルギー分野:企業M&A・提携分析
    Summary EDF Renewable Energy, Inc. (EDF Renewable Energy), formerly, enXco, Inc., is an integrated energy company. The company designs, develops, constructs and operates renewable energy projects in the biogas, biomass, hydro, solar, wind and marine energy sectors; and provides storage solutions. It …
  • Zweites Deutsches Fernsehen:企業の戦略的SWOT分析
    Zweites Deutsches Fernsehen - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Richoux Group Plc:企業の戦略・SWOT・財務情報
    Richoux Group Plc - Strategy, SWOT and Corporate Finance Report Summary Richoux Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • NW Natural Gas Co:企業の戦略的SWOT分析
    NW Natural Gas Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • O’Reilly Automotive, Inc. (ORLY):企業の財務・戦略的SWOT分析
    Summary O'Reilly Automotive Inc (O’Reilly) is a provider of automotive parts. The company offers automotive parts, tools, equipment, supplies and accessories. The company offers various services such as battery diagnostic testing; battery, wiper and bulb replacement; check and engine light code extr …
  • Galadari Hotels (Lanka) PLC :企業の戦略・SWOT・財務情報
    Galadari Hotels (Lanka) PLC - Strategy, SWOT and Corporate Finance Report Summary Galadari Hotels (Lanka) PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • HOCHTIEF AG:戦略・SWOT・企業財務分析
    HOCHTIEF AG - Strategy, SWOT and Corporate Finance Report Summary HOCHTIEF AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Intas Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Intas Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • China Mobile Limited:戦略・SWOT・企業財務分析
    China Mobile Limited - Strategy, SWOT and Corporate Finance Report Summary China Mobile Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • RaQualia Pharma Inc (4579):製薬・医療:M&Aディール及び事業提携情報
    Summary RaQualia Pharma Inc (RaQualia) is a drug development company that discovers and develops pharmaceutical compounds. The company offers products such as anidulafungin, ziprasidone, dalbavancin, 5-HT2B antagonist, motilin receptor agonist, potassium-competitive acid blockerand 5-HT4 partial ago …
  • Nanjing Pharmaceutical Co Ltd (600713):企業の財務・戦略的SWOT分析
    Nanjing Pharmaceutical Co Ltd (600713) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Arab Orient Insurance Company:企業の戦略・SWOT・財務情報
    Arab Orient Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Arab Orient Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Avivagen Inc (VIV):企業の財務・戦略的SWOT分析
    Summary Avivagen Inc (Avivagen), is a biotechnology company that provides drug development and animal healthcare products. It offers OxC-beta an active ingredient used to support the innate immune system and a healthy inflammatory condition of living beings. Avivagen's oxidized carotenoids promote a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆